Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies
| Autor: | Geert R. D'Haens, Pleuni Ooijevaar-de Heer, Dora Pascual Salcedo, Karin A van Schie, Johannan F. Brandse, Chamaida Plasencia, Theo Rispens, Gerrit Jan Wolbink, Simone Kruithof, T. Jurado |
|---|---|
| Přispěvatelé: | AII - Inflammatory diseases, Graduate School, Other departments, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Landsteiner Laboratory |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
congenital hereditary and neonatal diseases and abnormalities Urticaria medicine.drug_class Immunology Immunoglobulin E Monoclonal antibody General Biochemistry Genetics and Molecular Biology Antibodies law.invention Arthritis Rheumatoid Cohort Studies 03 medical and health sciences 0302 clinical medicine Rheumatology law immune system diseases Spondylarthritis medicine Flushing Immunology and Allergy Humans Infusions Intravenous 030203 arthritis & rheumatology biology business.industry Incidence (epidemiology) Pruritus nutritional and metabolic diseases hemic and immune systems medicine.disease Infliximab enzymes and coenzymes (carbohydrates) 030104 developmental biology Dyspnea Anti infliximab antibodies Rheumatoid arthritis Antirheumatic Agents Recombinant DNA biology.protein Spondylarthropathies Antibody business medicine.drug |
| Zdroj: | Annals of the rheumatic diseases, 76(7), 1285-1288. BMJ Publishing Group |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/annrheumdis-2016-211035 |
| Popis: | Objectives Controversy exists on the role of IgE antidrug antibodies (IgE-ADA) in infusion reactions (IR) on infliximab treatment, partly due to the lack of a positive control used for assay validation. We sought to (1) develop a robust assay to measure IgE-ADA, including a positive control, (2) determine the association between IgE-ADA and IR and (3) determine the incidence of IgE-ADA in infliximab treated patients. Methods A recombinant human IgE anti-infliximab monoclonal antibody was developed as standard and positive control. With this antibody, we set up a novel robust assay to measure IgE-ADA. IgE-ADA was determined in three retrospective cohorts (n=159) containing IR+ (n=37) and IR− (n=39), and longitudinal sera of 83 spondyloarthritis. Results IgE-ADA was found in 0/39 IR−, whereas 4/37 (11%) IR+ showed low levels (0.1–0.3 IU/mL, below the 0.35 IU/mL threshold associated with elevated risk of allergic symptoms). All patients who were IgE-ADA positive also had (very) high IgG-ADA levels. The incidence of IgE-ADA in patients with infliximab-treated spondyloarthritis was estimated at less than approximately 1%. Conclusions IgE-ADA is rarely detected in infliximab-treated patients. Moreover, the absence of IgE-ADA in the majority of IR+ patients suggests that IgE-ADA is not associated with infusion reactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|